Earlier studies have shown that urinary exosomal Wilms’ tumor-1 (WT-1) is a promising non-invasive biomarker with significant podocyte specificity, reflecting early podocyte injury in patients with FSGS (Zhou H. et al., 2013). Here, WT1 is linked to focal segmental glomerulosclerosis.